Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
22 May 2024
|
|
04:26 | Pegunigalsidase alfa-iwxj 3 changes history +1,266 [Alen Antony (3×)] | |||
|
|
04:26 (cur | prev) +459 Alen Antony talk contribs | ||||
|
|
04:06 (cur | prev) +752 Alen Antony talk contribs | ||||
|
|
03:57 (cur | prev) +55 Alen Antony talk contribs | ||||
| m 04:17 | Non-degenerate nucleotides per response element diffhist +1 Marshallsumter talk contribs (→Averages per Orders) | ||||
| 04:02 | FUTIBATINIB diffhist +3,715 Hafiza Amna Qadeer talk contribs | ||||
21 May 2024
|
|
m 22:47 | Non-degenerate nucleotides per response element 3 changes history −152 [Marshallsumter (3×)] | |||
| m |
|
22:47 (cur | prev) −45 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
20:11 (cur | prev) −50 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
18:25 (cur | prev) −57 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
N 22:01 | Vonoprazan, amoxicillin, and clarithromycin 2 changes history +8,611 [Rithish Nimmagadda (2×)] | |||
|
|
22:01 (cur | prev) +1,587 Rithish Nimmagadda talk contribs | ||||
| N |
|
18:33 (cur | prev) +7,024 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=vonoprazan, amoxicillin, and clarithromycin |aOrAn=a |drugClass=Potassium-competitive acid blocker |indicationType=treatment |indication=- erosive esophagitis (all grades) and relief of heartburn associated with erosive esophagitis in adults. ,Helicobacter pylori Infection |adverseReactions=-Common adverse reactions (≥2%) with vonoprazan when used for healing of erosive esophagitis: gastritis, diarrhea, abdom...") | |||
|
|
21:58 | User:Rithish Nimmagadda 4 changes history +68 [Rithish Nimmagadda (4×)] | |||
|
|
21:58 (cur | prev) −12 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
18:35 (cur | prev) +47 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
18:35 (cur | prev) +14 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
17:04 (cur | prev) +19 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 21:25 | Pegunigalsidase alfa-iwxj diffhist +824 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=pegunigalsidase alfa-iwxj |indicationType=treatment |indication=Fabry's disease in adults |hasBlackBoxWarning=Yes |adverseReactions=infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, and sinusitis. |blackBoxWarningTitle=HYPERSENSITIVITY REACTIONS including Anaphylaxis |blackBoxWarningBody=Patients may experience hypersensitivity reaction including a...") | ||||
| N 16:59 | Pirtobrutinib diffhist +4,566 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=pirtobrutinib |aOrAn=an |drugClass=noncovalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). |indicationType=treatment |indication=elapsed or refractory MCL in adults who have received at least 2 lines of prior systemic therapy, including a BTK inhibitor; designated an orphan drug by FDA for treatment of MCL and also in treatment of CLL or SLL in adults who have received at least 2 prior lines of th...") | ||||